-
Peijia Medical Completes First Two Implants of Trilogy THV System in Taiwan
•
China’s Peijia Medical Ltd (HKG: 9996) announced the completion of the first two implant surgeries using its Trilogy transcatheter heart valve (THV) System for the treatment of severe aortic valve regurgitation in Taiwan. Product DetailsThe Trilogy THV System, a proprietary transcatheter aortic valve replacement product with CE mark, is designed…
-
Peijia Medical Achieves First Compassionate Use of Taurus Trio TAVR System in Hong Kong
•
Peijia Medical Ltd (HKG: 9996), a leading medical device company, has announced the completion of its first compassionate use case utilizing the Taurus Trio transcatheter aortic valve replacement (TAVR) system in Hong Kong. This milestone marks a significant step in the application of the company’s advanced cardiovascular technology in the…
-
Peijia Medical Secures Exclusive Rights to NowYon’s YonFlow Device in Greater China
•
Peijia Medical Ltd (HKG: 9996) has entered into a licensing agreement with NowYon Medical, securing exclusive rights as the agent for NowYon’s YonFlow blood flow guidance device in Greater China. This eight-year partnership marks a significant collaboration between the two Chinese firms. The YonFlow device, recognized as the world’s first…
-
Edwards Lifesciences to Acquire Peijia Medical’s US Partner JenaValve, Impact on Licensing Deal Minimal
•
China-based Peijia Medical Ltd (HKG: 9996) has announced that its US-based partner JenaValve Technology Inc. will be acquired by Edwards Lifesciences Corporation through a merger agreement. This strategic acquisition comes as part of Edwards Lifesciences’ efforts to strengthen its structural heart portfolio. JenaValve had entered into a licensing agreement with…
-
Peijia Medical’s Taurus Atlas Pro Balloon Dilation Catheter Approved by NMPA for Pulmonary Valve Procedures
•
Peijia Medical Ltd (HKG: 9996) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its second-generation balloon dilation catheter, Taurus Atlas Pro. This non-compliant balloon is designed for percutaneous transluminal valvuloplasty of the pulmonary valve. The Taurus Atlas Pro balloon dilation catheter is…
-
Peijia Medical Commences Clinical Study for Taurus Trio TAVR System with First Patient Enrollment
•
Peijia Medical Ltd (HKG: 9996) has announced the enrollment of the first patient in a multi-center regulatory clinical study for its transcatheter aortic valve replacement (TAVR) system, Taurus Trio. This marks a significant milestone in the development and regulatory approval process for the company’s innovative cardiac device. Study Design and…
-
Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China
•
Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced receiving market approval from the National Medical Products Administration (NMPA) in China for its DCwire micro guide wire device. This milestone marks the company’s 15th neurointerventional product approval in China, highlighting its commitment to advancing…
-
Peijia Medical Achieves Milestone with First Commercial Implants of Trilogy TAVR System in Hong Kong
•
Peijia Medical Limited (HKG: 9996), a leading China-based medical device company, has announced the successful completion of the first two commercial implants using its transcatheter aortic valve replacement (TAVR) product, the Trilogy heart valve system, in Hong Kong. This marks a significant milestone as the Trilogy system is the first…
-
Peijia Medical Enrolls First Patient in GeminiOne TEER System Study
•
China’s Peijia Medical Ltd (HKG: 9996) announced first patient enrollment in a multi-center clinical study for its transcatheter edge-to-edge repair (TEER) system GeminiOne in China. The first operation went smoothly, with the whole device being manipulated for a mere 30 minutes. The prospective regulatory, multi-center, target value study is designed…
-
Peijia Medical Announces First Patient Implant in MonarQ TTVR System Clinical Study
•
China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global first-in-man (FIM) clinical study of its MonarQ transcatheter tricuspid valve replacement (TTVR) system. This marks a significant milestone in the development of innovative treatments for tricuspid regurgitation. MonarQ TTVR System ProfileThe MonarQ TTVR system is…
-
Peijia Medical Enrolls First Patient in HighLife TSMVR Study
•
China’s Peijia Medical Limited (HKG: 9996) has announced the enrollment of the first patient and the implantation in a regulatory clinical study for its HighLife transcatheter septal mitral valve replacement (TSMVR) system. This marks a significant step forward in the development and potential market approval of the device. Study Design…
